Patent · US Active

Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors

US12195450B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

THE JOHNS HOPKINS UNIVERSITY · US

Inventors

Takashi Tsukamoto · Ellicott City, US
Niyada Hin · Laurel, US
Ondrej Stepanek · Liberec, CZ
Barbara Slusher · Kingsville, US
Camilo Rojas · Baltimore, US
Ajit G. Thomas · Baltimore, US

Key dates

Filing date	Jan 29, 2020
Grant date	Jan 14, 2025
Priority date	—
Expiry date	Oct 28, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer or HIV-1, are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.